Alexion aims to advance NMOSD treatment landscape with exceptional Ultomiris efficacy data at ECTRIMS 2022
Results from CHAMPION-NMOSD trial demonstrated zero relapses with a median treatment duration of 73 weeks.Additional presentations will underscore debilitating emotional and physical toll of NMOSD on patients and caregivers, and highlight urgency to reduce disease burden.Alexion, AstraZeneca Rare Disease, will present new data showing significant advances for the treatment of anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, 26 to 28 October 2022.